$141.93 Million in Sales Expected for Evolent Health (EVH) This Quarter

Equities research analysts expect that Evolent Health (NYSE:EVH) will post $141.93 million in sales for the current fiscal quarter, Zacks reports. Nine analysts have made estimates for Evolent Health’s earnings, with the highest sales estimate coming in at $142.75 million and the lowest estimate coming in at $141.10 million. Evolent Health posted sales of $107.32 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 32.2%. The company is expected to announce its next earnings results on Monday, August 6th.

According to Zacks, analysts expect that Evolent Health will report full year sales of $577.47 million for the current financial year, with estimates ranging from $574.40 million to $580.40 million. For the next year, analysts expect that the business will report sales of $667.51 million per share, with estimates ranging from $653.96 million to $680.10 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Evolent Health.

Evolent Health (NYSE:EVH) last announced its earnings results on Wednesday, May 9th. The technology company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.06. The business had revenue of $139.70 million for the quarter, compared to analyst estimates of $140.89 million. Evolent Health had a negative return on equity of 2.16% and a negative net margin of 12.11%. The company’s quarterly revenue was up 31.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.14) EPS.

EVH has been the topic of a number of research analyst reports. ValuEngine upgraded Evolent Health from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. Zacks Investment Research upgraded Evolent Health from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a research note on Monday, May 14th. Canaccord Genuity decreased their target price on Evolent Health from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Wednesday, February 28th. Jefferies Group set a $22.00 target price on Evolent Health and gave the stock a “buy” rating in a research note on Tuesday, February 13th. Finally, Wells Fargo decreased their target price on Evolent Health from $27.00 to $20.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have assigned a buy rating to the company. Evolent Health has a consensus rating of “Buy” and an average price target of $24.90.

NYSE EVH traded down $0.03 during trading on Wednesday, reaching $19.50. The company’s stock had a trading volume of 441,100 shares, compared to its average volume of 852,689. The firm has a market capitalization of $1.52 billion, a P/E ratio of -27.86 and a beta of 1.04. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.12. Evolent Health has a one year low of $10.30 and a one year high of $27.50.

In other news, President Seth Blackley sold 85,596 shares of the company’s stock in a transaction dated Tuesday, May 8th. The stock was sold at an average price of $17.08, for a total value of $1,461,979.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Unitedhealth Group Inc sold 3,040,000 shares of the company’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $13.70, for a total value of $41,648,000.00. The disclosure for this sale can be found here. Insiders sold a total of 3,189,994 shares of company stock valued at $44,245,316 over the last quarter. Company insiders own 4.82% of the company’s stock.

A number of hedge funds have recently modified their holdings of EVH. Jane Street Group LLC purchased a new stake in Evolent Health during the 4th quarter valued at about $144,000. Quantbot Technologies LP boosted its holdings in Evolent Health by 111.4% during the 1st quarter. Quantbot Technologies LP now owns 10,815 shares of the technology company’s stock valued at $154,000 after acquiring an additional 5,698 shares during the period. Virtu Financial LLC purchased a new stake in Evolent Health during the 4th quarter valued at about $172,000. Fox Run Management L.L.C. purchased a new stake in Evolent Health during the 4th quarter valued at about $175,000. Finally, LPL Financial LLC purchased a new stake in Evolent Health during the 1st quarter valued at about $184,000.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

Get a free copy of the Zacks research report on Evolent Health (EVH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply